Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Global PIII Study for Zipalertinib Begins for 1st Line NSCLC: Taiho
Taiho Pharmaceutical said on August 7 that the company has commenced a global PIII clinical trial for its EGFR inhibitor zipalertinib for the first-line treatment of certain adult patients with non-small cell lung cancer (NSCLC) harboring the EGFR exon 20…
To read the full story
Related Article
- Taiho’s Zipalertinib Hits Primary Goal in 1st Line NSCLC Trial
August 17, 2026
BUSINESS
- European Pharma Chairs Urge Policy Shift on Innovative Drug Investment
September 25, 2026
- SymBio Inks Exclusive HHS License for BCV in Multiple Sclerosis
September 25, 2026
- Tokyo Court Blocks Toho’s Poison Pill Move; Company to Appeal
September 25, 2026
- Roche Proposes Ex-Takeda CEO Weber for Board
September 24, 2026
- Astellas Starts Setidegrasib PIII in KRAS G12D-Mutated NSCLC
September 24, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…